ArticleDigestion2012
In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine.
Article in Digestion, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- The effect of rebamipide on non-steroidal anti-inflammatory drug-induced gastro-enteropathy: a multi-center, randomized pilot study.The Korean journal of internal medicine · 2022Trial
- From pain relief to mucosal grief: A comprehensive review of NSAID enteropathy.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Current research status and trends of potassium-competitive acid blockers in the treatment of acid-related diseases: a bibliometric analysis.Frontiers in pharmacology · 2024Article
- Gastroprotective Effects of Oral Glycosaminoglycans with Sodium Alginate in an Indomethacin-Induced Gastric Injury Model in Rats.Veterinary sciences · 2023Article
- Association between eupatilin and reduction in small bowel bleeding in aspirin users and aspirin plus acid suppressant users.The Korean journal of internal medicine · 2023Article
- Amyloid-polysaccharide interfacial coacervates as therapeutic materials.Nature communications · 2023Article
- Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances.Molecules (Basel, Switzerland) · 2021Review
- Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugsOncology letters · 2018Article
- Non-steroidal anti-inflammatory drug-induced enteropathy.Intestinal research · 2017Review
- Suppression of calpain expression by NSAIDs is associated with inhibition of cell migration in rat duodenum.Toxicology · 2017Article
- Suppression of contractile activity in the small intestine by indomethacin and omeprazole.American journal of physiology. Gastrointestinal and liver physiology · 2015Article
- In vitro evidence that phosphatidylcholine protects against indomethacin/bile acid-induced injury to cells.American journal of physiology. Gastrointestinal and liver physiology · 2015Article
- Increased gap density predicts weakness of the epithelial barrier in vivo by confocal laser endomicroscopy in indomethacin-induced enteropathy.Digestive diseases and sciences · 2014Article
- Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges.Gastroenterology research and practice · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND/
aimsProton pump inhibitors (PPIs) are widely used to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcers. NSAIDs produce small intestinal injury and some PPIs have been reported to protect against NSAID-induced small bowel injury in rats. The aim of this study was to compare PPIs, revaprazan, and phosphatidylcholine-associated indomethacin (Indo-PC) for protection against indomethacin (Indo)-induced small bowel injury.
methodsRat intestinal epithelial cells (IEC-6) were pretreated with omeprazole, lansoprazole, or revaprazan prior to exposure to Indo or Indo-PC. Cell viability was assessed by methyl thiazolyl tetrazolium assay. Omeprazole, lansoprazole, or revaprazan was administered orally to rats prior to the vehicle or Indo. Indo-PC was administered alone. After 24 h, small intestinal erosions were counted; intestinal bleeding was assessed as the hemoglobin concentration of small intestinal fluid.
resultsOmeprazole, lansoprazole, and revaprazan did not protect against Indo-induced IEC-6 cell injury. Indo-PC was less damaging in vitro than Indo alone. In vivo, neither omeprazole nor lansoprazole protected against Indo-induced small bowel injury; however, revaprazan pretreatment and Indo-PC resulted in significantly fewer erosions (>50% reduction) or bleeding (>80% reduction).
conclusionPPIs showed no small bowel protective effect in vitro or in vivo. Revaprazan showed a small bowel protective effect in vivo, whereas Indo-PC was protective both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.